Lilly Wong is Vice President, Clinical Translation at Fate Therapeutics, where she oversees the development and implementation of translational strategies for clinical programs in hematology-oncology, solid tumors, and autoimmune diseases. With over 20 years of experience in translational research, Dr. Wong has expertise in biomarker discovery, clinical assay development, pharmacokinetics/pharmacodynamics (PK/PD), patient enrichment hypotheses, and combination strategies. Before joining Fate, Dr. Wong served as Director of Translational Medicine at Bristol Myers Squibb, where she led clinical biomarker development and combination strategies for a novel CELMoD in relapsed/refractory multiple myeloma. She also held several scientific and leadership roles at Celgene Corporation. Dr. Wong earned both her Ph.D. and B.S. in Chemistry and Biochemistry from the University of California, San Diego.

Vaneet K Sandhu is Vice President of Clinical Development at Fate Therapeutics, where she leads the development of the company’s clinical programs in autoimmunity. Previously, she was a practicing rheumatologist at Loma Linda University Health, serving as the Rheumatology Fellowship Program Directorm and Director of the rheumatology clinics at Riverside University Health System. Her academic contributions include leading numerous clinical trials, establishing lupus and systemic sclerosis registries, and conducting funded research on health services in patients with rheumatic disease and biomarker development in SLE. Vaneet earned her MBBS from Dayanand Medical College and Hospital (India) and an MS in Academic Medicine from the University of Missouri. She completed her Internal Medicine residency at Loma Linda University Health and Rheumatology fellowship at Cedars-Sinai Medical Center.

Victor Hong is Vice President, Corporate Development & Finance at Fate Therapeutics and is responsible for business development, finance, and business planning activities. Before joining Fate, he served as Vice President Hematology Strategy at BMS, guiding portfolio strategy and prioritization. Prior to that role, he was Executive Director Business Planning & Finance at Celgene, responsible for financial valuations of internal / external innovation, as well as new product planning and launch preparedness. He has over 20 years of industry experience in multiple therapeutic and functional areas, including market analysis at Novartis and clinical data operations at Pfizer. He holds an M.B.A. from Fordham University, an M.P.H. from Columbia University, and a B.S. in biomedical engineering from Boston University.

Jessica Francis is Vice President, Human Resources & Operations at Fate Therapeutics and is responsible for the company’s human resources, environmental health and safety, security and facilities management. Ms. Francis has more than 20 years of experience supporting biotechnology companies and has led Fate’s Human Resources function for over 15 years. Before joining Fate as one of the company’s first employees, Ms. Francis served in supporting roles in legal and administration at Immunex, Amgen, and iKaria. She served as the founding President of the Board of Trustees for the Beyond Benefits Trust, offering multiple employers competitive healthcare benefits options. Ms. Francis received her B.S. in Behavioral Science and Health from the University of Utah.

Yu Cai is the Head of Intellectual Property, Assistant General Counsel at Fate Therapeutics, where she oversees all aspects of IP protection and management across the company. With a unique combination of technical expertise and legal experience, Dr. Cai has led Fate’s IP practice for nearly a decade, building a proven track record in developing and executing global IP strategies, initiating and expanding high-value IP portfolios, guiding global patent prosecution, defending against third-party challenges, and advising on competitive landscape, freedom-to-operate, IP enforcement, and risk mitigation. Before joining Fate Therapeutics, Dr. Cai practiced IP law at Polsinelli, PC, where she served corporations in biotechnology and life sciences industries. She holds a Ph.D. in Plant Sciences and Genetics from the University of Arizona, specializing in epigenetics, as well as a M.S. in Biochemistry and Molecular Biology, and a B.S. in Biochemical Engineering. Dr. Cai obtained her J.D. from the Sandra Day O’Connor College of Law, Arizona State University.

Peter Burberry is Vice President, Information Technology at Fate Therapeutics and is responsible for the company’s information solutions, services and cybersecurity. Prior to joining Fate, Peter led Global IT teams for Aerie Pharmaceuticals (now Alcon), Allergan (now Abbvie) and Hologic. He has over 20 years of Biopharma/Pharmaceutical experience and has led large and small application roll outs across the world. Peter has a Batchelor of Science (Hons) from Loughborough University in the U.K.

Noreen Blanchett is Vice President, Deputy General Counsel at Fate Therapeutics and is responsible for day-to-day legal operations and providing legal counsel to all functions of the business, as well as supporting the Chief Legal & Compliance Officer in the areas of legal and risk management and corporate governance. Prior to joining Fate, Ms. Blanchett was Associate General Counsel at SeaSpine, Inc., a medical device company. Ms. Blanchett began her legal career as an associate in Latham & Watkins LLP’s finance department. Ms. Blanchett received her J.D. from the University of California, Los Angeles School of Law and a B.A. in Applied Mathematics from the University of California, Berkeley. She is admitted to the state bar of California.

Tunde Babalola is Senior Vice President, Technical Operations at Fate Therapeutics, overseeing all GxP operations, process development, quality and compliance activities. Dr. Babalola is an accomplished leader with more than 15 years of diverse experience spanning cell therapy, biologics, small molecules, combination products and medical implants. Before joining Fate, Dr. Babalola worked at Kite, A Gilead Company, leading quality control and quality assurance site organizations at Kite’s Clinical and Commercial facilities for Yescarta^® and Tecartus^®. Prior to that she held multiple roles of increasing responsibilities at Bristol Myers Squibb both at their corporate headquarters and at their manufacturing sites in Puerto Rico, including leading the successful US launches of Orencia^® SC and Nulogix^®, and as quality lead for Yervoy^® and Eliquis^® at critical commercial manufacturing and packaging facilities for global supply. Dr. Babalola received a B.Sc. in Biomedical Engineering with a concentration in Mechanical Engineering from the University of Rochester and a Ph.D. in Biomedical Engineering from Cornell University.

Mr. Henry is Senior Vice President, Clinical Operations at Fate Therapeutics and is responsible for the global implementation of the company’s clinical programs. He has over 35 years of experience managing clinical trials in global life science companies. Over the last decade, he has worked at the executive team level as the Sr. Vice President overseeing the Clinical Development Operations and Portfolio Management at several clinical-stage biotech companies delivering global programs in cell therapies, devices, and small molecules for Alcoholic Hepatitis, Becker Muscular Dystrophy, as well as Oncology portfolios. Mr. Henry has overseen large multi-million-dollar programs and portfolios across multiple therapeutic areas and has built and managed teams from 5 to 150 employees. At Schering-Plough Oncology, he was a part of the team that led to the approval of Temozolomide for treating brain cancers including glioblastoma multiforme (GBM) and anaplastic astrocytoma (AA). At Novartis Oncology, he led the joint clinical team in partnership with Schering AG, developing an early antiangiogenic compound in a global Phase 3 colorectal cancer program. Mr. Henry has a B.S. in Biology with Honors in Biopsychology and Behavioral Genetics from William Paterson University.

Cindy Tahl is Chief Legal & Compliance Officer at Fate Therapeutics and is serving as a key advisor in day to day operations, providing legal advice and counsel for all functions of the business and overseeing company compliance. Ms. Tahl also directs the development and expansion of the Company’s IP portfolio. Prior to joining Fate, Ms. Tahl was a technology transactions attorney at Wilson Sonsini Goodrich & Rosati, P.C., and practiced intellectual property law in the New York office of Kenyon & Kenyon, LLP. Ms. Tahl has worked extensively with biotechnology companies at all stages of growth, representing clients in numerous corporate transactions and executing patent strategy to advance corporate goals. Ms. Tahl received a J.D. from Boston College Law School and a B.S. in biology from the University of California, San Diego. She is admitted to the state bars of California and New York, and is registered to practice as a patent attorney before the U.S. Patent and Trademark Office.